All In Biotech

BLA 020604 · Emd Serono

Serostim

Somatropin · Injection, Subcutaneous

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Aug 23, 1996

Approved uses

3

Original approval plus efficacy supplements

Registered trials

540

176 Phase 3, 31 recruiting

FAERS reports

6,707

4,702 serious, 482 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 22, 2026.

SEROSTIM (somatropin) is indicated for the treatment of adults with HIV and wasting or cachexia to increase lean body mass and body weight, and improve physical endurance. Concomitant antiretroviral therapy is necessary. SEROSTIM is a human growth hormone (somatropin) indicated for the treatment of adults with HIV and wasting or cachexia to increase lean body mass and body weight, and improve physical endurance ( 1 )

Mechanism: Somatropin is an anabolic and anticatabolic agent which exerts its influence by interacting with growth hormone receptors on a variety of cell types including myocytes, hepatocytes, adipocytes, lymphocytes, and hematopoietic cells. Some, but not all of its effects, are mediated by insulin-like growth factor-1 (IGF-1).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 13, 2007 Supplement 40 · Efficacy ReviewLabelLetter
  • Aug 29, 2003 Supplement 27 · Efficacy ReviewLetterLabel
  • Aug 23, 1996 Original approval · Type 5 - New Formulation or New Manufacturer · priority review
5 products under this application
  • SEROSTIM · SOMATROPIN 4MG/VIAL · INJECTABLE, INJECTION · Prescription
  • SEROSTIM · SOMATROPIN 6MG/VIAL · INJECTABLE, INJECTION · Prescription
  • SEROSTIM · SOMATROPIN 8.8MG/VIAL · INJECTABLE, INJECTION · Discontinued
  • SEROSTIM · SOMATROPIN 5MG/VIAL · INJECTABLE, INJECTION · Prescription
  • SEROSTIM LQ · SOMATROPIN 6MG/0.5ML (6MG/0.5ML) · INJECTABLE, SUBCUTANEOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Somatropin" as an intervention, any sponsor and status, largest first.

All 540 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use446
  • device leakage334
  • headache252
  • injection site pain224
  • drug dose omission by device219
  • death211
  • fatigue191
  • drug ineffective155
  • device mechanical issue150
  • arthralgia142
  • device issue137
  • product dose omission issue135

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200448
200525
200637
2007122
200859
2009224
2010174
2011214
2012225
2013103
2014186
2015272
2016385
2017300
2018310
2019485
2020415
2021314
2022485
2023795
2024715
2025479
2026335

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Serostim (Somatropin)

2024 spending

$110M

Beneficiaries

612

5,396 claims

Per beneficiary

$178,947

$684.07 per unit

View as table
YearSpending
2020$102,791,575
2021$101,164,045
2022$104,635,733
2023$107,368,290
2024$109,515,830

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 84 on PubMed

Sponsor: Emd Serono · Also marketed as Serostim Lq

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.